文献速递肾癌与肾肿瘤

术前无慢性肾病的肾细胞癌患者术后新发慢性肾病(CKD-S)加重对生存的影响

Impact of worsening surgically induced chronic kidney disease (CKD-S) in preoperative CKD-naïve patients on survival in renal cell carcinoma.
PubMed 文献 · BJU Int · 2022-08-13

该回顾性分析纳入3239例术前无慢性肾病(eGFR≥60 mL/min/1.73 m²)且接受部分或根治性肾切除术的肾细胞癌患者,按末次随访时CKD-S分期分组。结果显示新发CKD-S 3b和4期与全因死亡和非癌死亡独立相关,而3a期无此关联。根治性肾切除术与CKD-S 3-4期独立相关。

要点

  • 新发CKD-S 3b和4期与全因死亡和非癌死亡独立相关,3a期无此关联。
  • 根治性肾切除术与CKD-S 3-4期独立相关(HR 1.78-1.99)。
  • 5年总生存率随CKD-S分期加重而下降:无CKD-S 84% vs 3a期78% vs 3b期71% vs 4期60%。

核心结论

  • 新发CKD-S 3b和4期(而非3a期)与全因死亡和非癌死亡恶化相关。
  • 是否选择部分肾切除术以保留肾单位应基于肿瘤学风险和功能下降至CKD-S 3b或4期(而非3a期)的风险进行个体化决策。

研究设计与样本

  • 回顾性分析纳入3239例接受部分或根治性肾切除术且术前无慢性肾病(eGFR≥60 mL/min/1.73 m²)的肾细胞癌患者。
  • 按末次随访时CKD-S分期分组:无CKD-S(eGFR≥60)、新发CKD-S 3a(eGFR 45-59)、CKD-S 3b(eGFR<45且≥30)和CKD-S 4(eGFR<30且≥15 mL/min/1.73 m²)。
  • 主要结局为全因死亡,次要结局包括非癌死亡、癌症特异性死亡和新发CKD-S 3/4期。

主要发现

  • 末次随访时,57.9%(n=1876)无CKD-S,18.7%(n=606)为CKD-S 3a,15.1%(n=489)为CKD-S 3b,8.3%(n=268)为CKD-S 4。
  • 多变量分析显示,新发CKD-S 3b和4期与全因死亡独立相关(HR 1.3-2.1,P=0.003-0.001),与 非癌死亡独立相关(HR 1.5-2.8,P=0.021-0.001),但与癌症特异性死亡无关(P=0.219-0.909)。
  • 新发CKD-S 3a期对任何死亡结局均无预测价值(P=0.102-0.81)。
  • 根治性肾切除术与CKD-S 3-4期独立相关(HR 1.78-1.99,P<0.001-0.035)。
  • Kaplan-Meier分析显示,随着CKD-S分期加重,5年总生存率(无CKD-S 84% vs 3a期78% vs 3b期71% vs 4期60%,P<0.001)和5年非癌生存率(93% vs 87% vs 83% vs 72%,P<0.001)均逐渐恶化。

临床怎么用

  • 作者认为,是否选择部分肾切除术以保留肾单位应基于肿瘤学风险和功能下降至CKD-S 3b或4期(而非3a期)的风险进行个体化决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate effects of worsening surgically induced chronic kidney disease (CKD-S) on oncological and non-oncological survival outcomes in renal cell carcinoma (RCC). PATIENTS AND METHODS: We performed a retrospective analysis of patients who underwent partial (PN) or radical nephrectomy (RN) and were free of preoperative CKD (estimated glomerular filtration rate [eGFR] ≥60 mL/min/1.73 m2 ). Patients were stratified by CKD stage at last follow-up: no CKD-S (eGFR ≥60 mL/min/1.73 m2 ), de novo CKD-S 3a (eGFR 45-59 mL/min/1.73 m2 ), CKD-S 3b (eGFR <45 and ≥30 mL/min/1.73 m2 ) and CKD-S 4 (eGFR <30 and ≥15 mL/min/1.73 m2 ). The primary outcome was all-cause mortality (ACM). Secondary outcomes included non-cancer mortality (NCM), cancer-specific mortality (CSM) and de novo CKD-S Stage 3/4. Multivariable analysis (MVA) was utilised to identify risk factors for outcomes. Kaplan-Meier analysis (KMA) was utilised to evaluate overall (OS), non-cancer (NCS), and cancer-specific survival with respect to CKD-S categories. RESULTS: We analysed 3239 patients. The mean preoperative and last-follow-up eGFRs were 87.4 and 69.5 mL/min/1.73 m2 , respectively. On last follow-up, 57.9% (n = 1876) had no CKD-S, 18.7% (n = 606) had CKD-S 3a, 15.1% (n = 489) had CKD-S 3b and 8.3% (n = 268) had CKD-S 4. On MVA, de novo CKD-S 3b and 4 were independently associated with ACM (hazard ratios [HRs] 1.3-2.1, P = 0.003-0.001) and NCM (HRs 1.5-2.8, P = 0.021-0.001), but not CSM (P = 0.219-0.909); de novo CKD-S 3a was not predictive for any mortality outcomes (P = 0.102-0.81). RN was independently associated with CKD-S 3-4 (HRs 1.78-1.99, P < 0.001-0.035). Comparing no CKD-S, CKD-S 3a, CKD-S 3b and CKD-S 4, KMA demonstrated worsening outcomes with progressive CKD-S stage: 5-year OS 84% vs 78% vs 71% vs 60% (P < 0.001) and 5-year NCS 93% vs 87% vs 83% vs 72% (P < 0.001). CONCLUSION: Development of CKD-S Stage 3b and 4, but not 3a, was associated with worsened ACM and NCM. The decision to proceed with nephron preservation via PN should be individualised based on oncological risk and risk of functional decline to CKD-S 3b or 4, and not CKD-S 3a.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Nguyen MV, Walia A, Saidian A, et al. Impact of worsening surgically induced chronic kidney disease (CKD-S) in preoperative CKD-naïve patients on survival in renal cell carcinoma. BJU Int. 2022. PMID: 35876044. doi:10.1111/bju.15861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。